Medifast, Inc. (MED)

Medifast's stock price has been significantly impacted by negative events, including revenue declines and net losses. In Q4 2025, revenue decreased by 36.9% to $75.1 million, with a net loss of $18.1 million. Full-year 2025 revenue fell by 36.0% to $385.8 million, resulting in a net loss of $18.7 million, driven by a decrease in active earning coaches and the adoption of GLP-1 medications. The stock price has declined by 18.85% over the past year. Q1 2026 revenue is projected to be between $65 million and $80 million, with a loss per share ranging from $0.15 to $0.70. Full-year 2026 revenue is expected to be between $270 million and $300 million, with a loss per share between $1.55 and $2.75. The company maintains a strong balance sheet with $167.3 million in cash, cash equivalents, and investment securities and no debt at the end of 2025.

While specific data on Medifast's demand seasonality is not readily available, the company's revenue model is supported by the recurrent nature of product consumption. This suggests relatively consistent demand throughout the year. General market seasonality trends are available through financial platforms, and the company's focus on long-term healthy habits may contribute to a more stable demand profile.

Medifast, Inc. is a health and wellness company specializing in weight management and healthy living solutions, founded in 1980. The company operates in the Consumer Cyclical sector, focusing on weight loss and multi-level marketing through its OPTAVIA brand, which offers a coach-guided lifestyle solution. Medifast's products include meal replacements like shakes, bars, soups, and snacks, along with lifestyle programs such as the 5 & 1 Plan and OPTAVIA GLP-1 Nutrition Support Plan. The business model uses direct selling through independent OPTAVIA Coaches.

Medifast, Inc. primarily operates in the United States, with its headquarters in Baltimore, Maryland. The company has pursued international expansion through strategic partnerships aimed at increasing distribution to countries across Mexico, Central America, and South America, including Argentina, Bolivia, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Venezuela, and Uruguay.

Medifast's brand reputation has likely been affected by its financial decline and the rise of GLP-1 medications. The company is repositioning itself to focus on metabolic health rather than just weight loss. There are risks to brand image from potential health or advertising-related claims and adverse publicity. While Medifast has received accolades in the past, maintaining and rebuilding brand reputation is now crucial due to recent financial downturn and competitive pressures.

Medifast, Inc. has a mixed ownership structure including institutional, retail, and individual investors. As of April 9, 2026, there are 116 institutional owners holding 8,064,222 shares, representing approximately 66.34% ownership. Major institutional shareholders include BlackRock, Inc., Renaissance Technologies Llc, Charles Schwab Investment Management Inc, Vanguard Group Inc, Citadel Advisors Llc, Morgan Stanley, Lido Advisors, LLC, Dimensional Fund Advisors Lp, Steamboat Capital Partners, LLC, and Jane Street Group, Llc. Retail ownership is estimated at around 50.77%, and insider ownership is approximately 4.71%.